Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice

DMM Disease Models and Mechanisms

Volumn 6, Issue 1, 2013, Pages 171-183

  Zurkovsky, Lilia ^a   Bychkov, Evgeny ^a,c   Tsakem, Elviche L ^a   Siedlecki, Carley ^a   Blakely, Randy D ^a,b   Gurevich, Eugenia V ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c S M KIROV MILITARY MEDICAL ACADEMY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; DONEPEZIL; DOPAMINE; OXIDOPAMINE; PHYSOSTIGMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; EXECUTIVE FUNCTION; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PARKINSON DISEASE DEMENTIA; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPATIAL MEMORY; VISUAL MEMORY;

ACETYLCHOLINE; ANIMALS; CHOLINERGIC AGENTS; COGNITION DISORDERS; DEMENTIA; DISEASE MODELS, ANIMAL; DOPAMINE; HEMICHOLINIUM 3; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MEMORY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PARKINSONIAN DISORDERS; SIGNAL TRANSDUCTION;

MUS; RODENTIA;

EID: 84872070570     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.010363     Document Type: Article

References (97)

1. Aarsland, D. and Kurz, M. W. (2010). The epidemiology of dementia associated with Parkinson disease. J. Neurol. Sci. 289, 18-22.
2. Aarsland, D., Laake, K., Larsen, J. P. and Janvin, C. C. (2002). Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry 72, 708-712.
3. Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A. and Kragh-Sørensen, P. (2003). Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60, 387-392.
4. Aarsland, D., Perry, R., Brown, A., Larsen, J. P. and Ballard, C. (2005). Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann. Neurol. 58, 773-776.
5. Aarsland, D., Brønnick, K. and Fladby, T. (2011). Mild cognitive impairment in Parkinson's disease. Curr. Neurol. Neurosci. Rep. 11, 371-378.
6. Ahmed, M. R., Bychkov, E., Gurevich, V. V., Benovic, J. L. and Gurevich, E. V. (2008). Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment. J. Neurochem. 104, 1622-1636.
7. Ahmed, M. R., Berthet, A., Bychkov, E., Porras, G., Li, Q., Bioulac, B. H., Carl, Y. T., Bloch, B., Kook, S., Aubert, I. et al. (2010). Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci. Transl. Med. 2, ra28.
8. Aho, L., Parkkinen, L., Pirttilä, T. and Alafuzoff, I. (2008). Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects. Dement. Geriatr. Cogn. Disord. 25, 423-432.
9. Ardayfio, P., Moon, J., Leung, K. K. A., Youn-Hwang, D. and Kim, K.-S. (2008). Impaired learning and memory in Pitx3 deficient aphakia mice: a genetic model for striatum-dependent cognitive symptoms in Parkinson's disease. Neurobiol. Dis. 31, 406-412.
10. Bazalakova, M. H., Wright, J., Schneble, E. J., McDonald, M. P., Heilman, C. J., Levey, A. I. and Blakely, R. D. (2007). Deficits in acetylcholine homeostasis, receptors and behaviors in choline transporter heterozygous mice. Genes Brain Behav. 6, 411-424.
11. Beatty, W. W. and Monson, N. (1990). Problem solving in Parkinson's disease: comparison of performance on the Wisconsin and California Card Sorting Tests. J. Geriatr. Psychiatry Neurol. 3, 163-171.
12. Beatty, W. W., Staton, R. D., Weir, W. S., Monson, N. and Whitaker, H. A. (1989). Cognitive disturbances in Parkinson's disease. J. Geriatr. Psychiatry Neurol. 2, 22-33.
13. Bertrand, N., Beley, P. and Beley, A. (1994). Brain fixation for acetylcholine measurements. J. Neurosci. Methods 53, 81-85.
14. Birrell, J. M. and Brown, V. J. (2000). Medial frontal cortex mediates perceptual attentional set shifting in the rat. J. Neurosci. 20, 4320-4324.
15. Bissonette, G. B., Martins, G. J., Franz, T. M., Harper, E. S., Schoenbaum, G. and Powell, E. M. (2008). Double dissociation of the effects of medial and orbital prefrontal cortical lesions on attentional and affective shifts in mice. J. Neurosci. 28, 11124-11130.
16. Bohnen, N. I., Kaufer, D. I., Ivanco, L. S., Lopresti, B., Koeppe, R. A., Davis, J. G., Mathis, C. A., Moore, R. Y. and DeKosky, S. T. (2003). Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. 60, 1745-1748.
17. Bohnen, N. I., Kaufer, D. I., Hendrickson, R., Ivanco, L. S., Lopresti, B. J., Constantine, G. M., Mathis, C. A., Davis, J. G., Moore, R. Y. and Dekosky, S. T. (2006). Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J. Neurol. 253, 242-247.
18. Braga, R., Kouzmine, I., Canteras, N. S. and Da Cunha, C. (2005). Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats. Exp. Neurol. 192, 134-141.
19. Branchi, I., D'Andrea, I., Armida, M., Cassano, T., Pèzzola, A., Potenza, R. L., Morgese, M. G., Popoli, P. and Alleva, E. (2008). Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J. Neurosci. Res. 86, 2050-2061.
20. Bychkov, E. R., Gurevich, V. V., Joyce, J. N., Benovic, J. L. and Gurevich, E. V. (2008). Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia. Neurobiol. Aging 29, 379-396.
21. Campbell, N., Boustani, M., Limbil, T., Ott, C., Fox, C., Maidment, I., Schubert, C. C., Munger, S., Fick, D., Miller, D. et al. (2009). The cognitive impact of anticholinergics: a clinical review. Clin. Interv. Aging 4, 225-233.
22. Chen, K. C., Baxter, M. G. and Rodefer, J. S. (2004). Central blockade of muscarinic cholinergic receptors disrupts affective and attentional set-shifting. Eur. J. Neurosci. 20, 1081-1088.
23. Choi, S. H., Jung, T. M., Lee, J. E., Lee, S.-K., Sohn, Y. H. and Lee, P. H. (2012). Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status. Neurobiol. Aging 33, 1265-1272.
24. Colacicco, G., Welzl, H., Lipp, H.-P. and Würbel, H. (2002). Attentional set-shifting in mice: modification of a rat paradigm, and evidence for strain-dependent variation. Behav. Brain Res. 132, 95-102.
25. Colloby, S. J., Williams, E. D., Burn, D. J., Lloyd, J. J., McKeith, I. G. and O'Brien, J. T. (2005). Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur. J. Nucl. Med. Mol. Imaging 32, 1176-1185.
26. Cools, R., Barker, R. A., Sahakian, B. J. and Robbins, T. W. (2001). Mechanisms of cognitive set flexibility in Parkinson's disease. Brain 124, 2503-2512.
27. Da Cunha, C., Silva, M. H. C., Wietzikoski, S., Wietzikoski, E. C., Ferro, M. M., Kouzmine, I. and Canteras, N. S. (2006). Place learning strategy of substantia nigra pars compacta-lesioned rats. Behav. Neurosci. 120, 1279-1284.
28. Damsma, G., Westerink, B. H. C. and Horn, A. S. (1985). A simple, sensitive, and economic assay for choline and acetylcholine using HPLC, an enzyme reactor, and an electrochemical detector. J. Neurochem. 45, 1649-1652.
29. De Leonibus, E., Pascucci, T., Lopez, S., Oliverio, A., Amalric, M. and Mele, A. (2007). Spatial deficits in a mouse model of Parkinson disease. Psychopharmacology (Berl.) 194, 517-525.
30. Decamp, E., Tinker, J. P. and Schneider, J. S. (2004). Attentional cueing reverses deficits in spatial working memory task performance in chronic low dose MPTP-treated monkeys. Behav. Brain Res. 152, 259-262.
31. Dias, R., Robbins, T. W. and Roberts, A. C. (1996). Dissociation in prefrontal cortex of affective and attentional shifts. Nature 380, 69-72.
32. Dunnett, S. B. and Lelos, M. (2010). Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease. Prog. Brain Res. 184, 35-51.
33. Dunois, B., Ruberg, M., Javoy-Agid, F., Ploska, A. and Agid, Y. (1983). A subcorticocortical cholinergic system is affected in Parkinson's disease. Brain Res. 288, 213-218.
34. Edison, P., Rowe, C. C., Rinne, J. O., Ng, S., Ahmed, I., Kemppainen, N., Villemagne, V. L., O'Keefe, G., Någren, K., Chaudhury, K. R. et al. (2008). Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J. Neurol. Neurosurg. Psychiatry 79, 1331-1338.
35. Emre, M. (2004). Dementia in Parkinson's disease: cause and treatment. Curr. Opin. Neurol. 17, 399-404.
36. Ferguson, S. M., Savchenko, V., Apparsundaram, S., Zwick, M., Wright, J., Heilman, C. J., Yi, H., Levey, A. I. and Blakely, R. D. (2003). Vesicular localization and activity-dependent trafficking of presynaptic choline transporters. J. Neurosci. 23, 9697-9709.
37. Ferguson, S. M., Bazalakova, M., Savchenko, V., Tapia, J. C., Wright, J. and Blakely, R. D. (2004). Lethal impairment of cholinergic neurotransmission in hemicholinium-3-sensitive choline transporter knockout mice. Proc. Natl. Acad. Sci. USA 101, 8762-8767.
38. Ferro, M. M., Bellissimo, M. I., Anselmo-Franci, J. A., Angellucci, M. E., Canteras, N. S. and Da Cunha, C. (2005). Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J. Neurosci. Methods 148, 78-87.
39. Fuchs, G. A., Gemende, I., Herting, B., Lemke, M. R., Oehlwein, C., Reichmann, H., Rieke, J., Emmans, D., Volkmann, J., (2004) Dementia in idiopathic Parkinson's syndrome. J. Neurol. 251 Suppl. 6, 28-32.
40. Games, P. A. and Howell, J. F. (1976). Pairwase multiple comparison procedures with unequal n's and/or variances: A Monte Carlo study. J. Educ. Stat. 1, 113-125.
41. Garner, J. P., Thogerson, C. M., Würbel, H., Murray, J. D. and Mench, J. A. (2006). Animal neuropsychology: validation of the Intra-Dimensional Extra-Dimensional set shifting task for mice. Behav. Brain Res. 173, 53-61.
42. Giladi, N., Shabtai, H., Gurevich, T., Benbunan, B., Anca, M. and Korczyn, A. D. (2003). Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol. Scand. 108, 368-373.
43. Halliday, G., Hely, M., Reid, W. and Morris, J. (2008). The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 115, 409-415.
44. Hasselmo, M. E. and Sarter, M. (2011). Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 36, 52-73.
45. Hefco, V., Yamada, K., Hefco, A., Hritcu, L., Tiron, A. and Nabeshima, T. (2003). Role of the mesotelencephalic dopamine system in learning and memory processes in the rat. Eur. J. Pharmacol. 475, 55-60.
46. Higginson, C. I., Wheelock, V. L., Carroll, K. E. and Sigvardt, K. A. (2005). Recognition memory in Parkinson's disease with and without dementia: evidence inconsistent with the retrieval deficit hypothesis. J. Clin. Exp. Neuropsychol. 27, 516-528.
47. Hilker, R., Thomas, A. V., Klein, J. C., Weisenbach, S., Kalbe, E., Burghaus, L., Jacobs, A. H., Herholz, K. and Heiss, W. D. (2005). Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65, 1716-1722.
48. Hurtig, H. I., Trojanowski, J. Q., Galvin, J., Ewbank, D., Schmidt, M. L., Lee, V. M., Clark, C. M., Glosser, G., Stern, M. B., Gollomp, S. M. et al. (2000). Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54, 1916-1921.
49. Hutchinson, M. and Fazzini, E. (1996). Cholinesterase inhibition in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 61, 324-325.
50. Ito, K., Nagano-Saito, A., Kato, T., Arahata, Y., Nakamura, A., Kawasumi, Y., Hatano, K., Abe, Y., Yamada, T., Kachi, T. et al. (2002). Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 125, 1358-1365.
51. Janvin, C. C., Aarsland, D. and Larsen, J. P. (2005). Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. J. Geriatr. Psychiatry Neurol. 18, 149-154.
52. Jellinger, K. A. (2009). A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim. Biophys. Acta 1792, 730-740.
53. Jellinger, K. A., Seppi, K., Wenning, G. K. and Poewe, W. (2002). Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J. Neural Transm. 109, 329-339.
54. Johnson, D. K. and Galvin, J. E. (2011). Longitudinal changes in cognition in Parkinson's disease with and without dementia. Dement. Geriatr. Cogn. Disord. 31, 98-108.
55. Joyce, J. N., Ryoo, H. L., Beach, T. B., Caviness, J. N., Stacy, M., Gurevich, E. V., Reiser, M. and Adler, C. H. (2002). Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res. 955, 138-152.
56. Kehagia, A. A., Barker, R. A. and Robbins, T. W. (2010). Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 9, 1200-1213.
57. Klein, J. C., Eggers, C., Kalbe, E., Weisenbach, S., Hohmann, C., Vollmar, S., Baudrexel, S., Diederich, N. J., Heiss, W. D. and Hilker, R. (2010). Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 74, 885-892.
58. Klinkenberg, I. and Blokland, A. (2010). The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci. Biobehav. Rev. 34, 1307-1350.
59. Kuhl, D. E., Minoshima, S., Fessler, J. A., Frey, K. A., Foster, N. L., Ficaro, E. P., Wieland, D. M. and Koeppe, R. A. (1996). In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann. Neurol. 40, 399-410.
60. Kurtz, A. and Kaufer, D. (2011). Dementia in Parkinson's disease. Curr. Treat. Options Neurol. 13, 242-254.
61. Kuzis, G., Sabe, L., Tiberti, C., Merello, M., Leiguarda, R. and Starkstein, S. E. (1999). Explicit and implicit learning in patients with Alzheimer disease and Parkinson disease with dementia. Neuropsychiatry Neuropsychol. Behav. Neurol. 12, 265-269.
62. Lange, K. W., Wells, F. R., Jenner, P. and Marsden, C. D. (1993). Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J. Neurochem. 60, 197-203.
63. Leroi, I., Brandt, J., Reich, S. G., Lyketsos, C. G., Grill, S., Thompson, R. and Marsh, L. (2004). Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int. J. Geriatr. Psychiatry 19, 1-8.
64. Lindner, M. D., Cain, C. K., Plone, M. A., Frydel, B. R., Blaney, T. J., Emerich, D. F. and Hoane, M. R. (1999). Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behav. Brain Res. 102, 1-16.
65. Lindsey, J. W., Jung, A. E., Narayanan, T. K. and Ritchie, G. D. (1998). Acute effects of a bicyclophosphate neuroconvulsant on monoamine neurotransmitter and metabolite levels in the rat brain. J. Toxicol. Environ. Health 54, 421-429.
66. Lipina, S. J. and Colombo, J. A. (2007). Premorbid exercising in specific cognitive tasks prevents impairment of performance in parkinsonian monkeys. Brain Res. 1134, 180-186.
67. Litvan, I., Mohr, E., Williams, J., Gomez, C. and Chase, T. N. (1991). Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 54, 25-29.
68. Maidment, I., Fox, C. and Boustani, M. (2006). Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst. Rev. 1, CD004747.
69. Mattila, P. M., Rinne, J. O., Helenius, H., Dickson, D. W. and Röyttä, M. (2000). Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. 100, 285-290.
70. McAlonan, K. and Brown, V. J. (2003). Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat. Behav. Brain Res. 146, 97-103.
71. McGaughy, J., Ross, R. S. and Eichenbaum, H. (2008). Noradrenergic, but not cholinergic, deafferentation of prefrontal cortex impairs attentional set-shifting. Neuroscience 153, 63-71.
72. Miyoshi, E., Wietzikoski, S., Camplessei, M., Silveira, R., Takahashi, R. N. and Da Cunha, C. (2002). Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Res. Bull. 58, 41-47.
73. Monchi, O., Petrides, M., Doyon, J., Postuma, R. B., Worsley, K. and Dagher, A. (2004). Neural bases of set-shifting deficits in Parkinson's disease. J. Neurosci. 24, 702-710.
74. Moriguchi, S., Yabuki, Y. and Fukunaga, K. (2012). Reduced calcium/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-treated mice. J. Neurochem. 120, 541-551.
75. Mosimann, U. P., Mather, G., Wesnes, K. A., O'Brien, J. T., Burn, D. J. and McKeith, I. G. (2004). Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 63, 2091-2096.
76. Muslimović, D., Schmand, B., Speelman, J. D. and de Haan, R. J. (2007). Course of cognitive decline in Parkinson's disease: a meta-analysis. J. Int. Neuropsychol. Soc. 13, 920-932.
77. Nakano, I. and Hirano, A. (1984). Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann. Neurol. 15, 415-418.
78. Noe, E., Marder, K., Bell, K. L., Jacobs, D. M., Manly, J. J. and Stern, Y. (2004). Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov. Disord. 19, 60-67.
79. Owen, A. M., Roberts, A. C., Hodges, J. R., Summers, B. A., Polkey, C. E. and Robbins, T. W. (1993a). Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease. Brain 116, 1159-1175.
80. Owen, A. M., Beksinska, M., James, M., Leigh, P. N., Summers, B. A., Marsden, C. D., Quinn, N. P., Sahakian, B. J. and Robbins, T. W. (1993b). Visuospatial memory deficits at different stages of Parkinson's disease. Neuropsychologia 31, 627-644.
81. Perretta, J. G., Pari, G. and Beninger, R. J. (2005). Effects of Parkinson disease on two putative nondeclarative learning tasks: probabilistic classification and gambling. Cogn. Behav. Neurol. 18, 185-192.
82. Perry, E. K., Curtis, M., Dick, D. J., Candy, J. M., Atack, J. R., Bloxham, C. A., Blessed, G., Fairbairn, A., Tomlinson, B. E. and Perry, R. H. (1985). Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 48, 413-421.
83. Perry, R. H., Perry, E. K., Smith, C. J., Xuereb, J. H., Irving, D., Whitford, C. A., Candy, J. M. and Cross, A. J. (1987). Cortical neuropathological and neurochemical substrates of Alzheimer's and Parkinson's diseases. J. Neural Transm. Suppl. 24, 131-136.
84. Prado, V. F., Martins-Silva, C., de Castro, B. M., Lima, R. F., Barros, D. M., Amaral, E., Ramsey, A. J., Sotnikova, T. D., Ramirez, M. R., Kim, H. G. et al. (2006). Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron 51, 601-612.
85. Robottom, B. J. and Weiner, W. J. (2009). Dementia in Parkinson's disease. Int. Rev. Neurobiol. 84, 229-244.
86. Ruberg, M., Ploska, A., Javoy-Agid, F. and Agid, Y. (1982). Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Res. 232, 129-139.
87. Sawamoto, N., Piccini, P., Hotton, G., Pavese, N., Thielemans, K. and Brooks, D. J. (2008). Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 131, 1294-1302.
88. Tadaiesky, M. T., Dombrowski, P. A., Figueiredo, C. P., Cargnin-Ferreira, E., Da Cunha, C. and Takahashi, R. N. (2008). Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 156, 830-840.
89. Tait, D. S. and Brown, V. J. (2008). Lesions of the basal forebrain impair reversal learning but not shifting of attentional set in rats. Behav. Brain Res. 187, 100-108.
90. Tait, D. S., Brown, V. J., Farovik, A., Theobald, D. E., Dalley, J. W. and Robbins, T. W. (2007). Lesions of the dorsal noradrenergic bundle impair attentional set-shifting in the rat. Eur. J. Neurosci. 25, 3719-3724.
91. Tröster, A. I., Fields, J. A., Testa, J. A., Paul, R. H., Blanco, C. R., Hames, K. A., Salmon, D. P. and Beatty, W. W. (1998). Cortical and subcortical influences on clustering and switching in the performance of verbal fluency tasks. Neuropsychologia 36, 295-304.
92. Tzavos, A., Jih, J. and Ragozzino, M. E. (2004). Differential effects of M1 muscarinic receptor blockade and nicotinic receptor blockade in the dorsomedial striatum on response reversal learning. Behav. Brain Res. 154, 245-253.
93. Varanese, S., Perfetti, B., Monaco, D., Thomas, A., Bonanni, L., Tiraboschi, P. and Onofrj, M. (2010). Fluctuating cognition and different cognitive and behavioural profiles in Parkinson's disease with dementia: comparison of dementia with Lewy bodies and Alzheimer's disease. J. Neurol. 257, 1004-1011.
94. Whitehouse, P. J., Hedreen, J. C., White, C. L., 3rd and Price, D. L. (1983). Basal forebrain neurons in the dementia of Parkinson disease. Ann. Neurol. 13, 243-248.
95. Williams-Gray, C. H., Foltynie, T., Lewis, S. J. and Barker, R. A. (2006). Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs 20, 477-505.
96. Wisman, L. A. B., Sahin, G., Maingay, M., Leanza, G. and Kirik, D. (2008). Functional convergence of dopaminergic and cholinergic input is critical for hippocampus-dependent working memory. J. Neurosci. 28, 7797-7807.
97. Wood, E. R., Dudchenko, P. A. and Eichenbaum, H. (1999). The global record of memory in hippocampal neuronal activity. Nature 397, 613-616.